ArticleGastroenterology report2026
Association between use of non-aspirin non-steroidal anti-inflammatory drugs and detection of colorectal polyps and cancer in a screening setting.
Article in Gastroenterology report, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While substantial evidence supports a protective effect of aspirin against colorectal polyps and cancer, the evidence for non-aspirin non-steroidal anti-inflammatory drugs (NA-NSAIDs) remains limited. We studied the association between the use of NA-NSAIDs and the detection of colorectal polyps and cancer among screening participants. Methods: We selected participants in the Bowel Cancer Screening trial in Norway-a randomized trial comparing once-only sigmoidoscopy and the biennial faecal immunochemical test (FIT). Using multivariable logistic regression, we estimated odds ratios (ORs) and 95% confidence intervals (CIs) for the association between NA-NSAID use in the 4 years before the screening invitation and detection of colorectal cancer (CRC), adenomas, advanced adenomas, and advanced serrated polyps. Long-term use was defined as ≥2 years of use. Results: Of 64,889 participants (24,159 sigmoidoscopy, 40,730 FIT), 35,867 (55.3%) were NA-NSAID users, 314 (0.5%) had CRC, 6,208 (9.6%) had adenomas, and 659 (1.0%) had advanced serrated polyps. NA-NSAID users had lower odds of CRC (OR 0.80; 95% CI 0.64-1.00), adenomas (OR 0.94; 95% CI 0.89-1.00), and advanced adenomas (OR 0.87; 95% CI 0.80-0.95) than those with no NA-NSAID prescription. For non-selective NA-NSAIDs, the results were similar to those for any NA-NSAIDs (CRC: OR 0.79, 95% CI 0.63-0.99; adenomas: OR 0.93, 95% CI 0.88-0.99; advanced adenomas: OR 0.87, 95% CI 0.79-0.95). COX2-selective NA-NSAIDs were not associated with CRC or adenomas. Among the long-term NA-NSAIDs users, the ORs were 0.59 (95% CI 0.27-1.26) for CRC, 0.65 (95% CI 0.54-0.79) for adenomas, and 0.59 (95% CI 0.44-0.80) for advanced adenomas. No association was observed between any NA-NSAID use and advanced serrated polyps. The results were consistent across trial arms and sexes. Conclusion: Our findings suggest that use of NA-NSAIDs, in particular non-selective NA-NSAIDs, might be associated with a reduced risk of adenomas and CRC, but not advanced serrated polyps.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.